An observational study in Coronary Artery Disease, Percutaneous Coronary Intervention and Acute Myocardial Infarction, sponsored by Zhejiang Provincial People's Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-17.
Sponsored by Zhejiang Provincial People's Hospital · Observational
The aim of this study is to investigate the potential novel risk factors for acute myocardial infarction. Predictors of poor outcomes will be also evaluated.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Zhejiang Provincial People's Hospital is the lead sponsor of 60 studies on the registry; 41 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients presenting to an emergency room and diagnosed as acute myocardial infarction
Exclusion Criteria:
Major adverse cardiovascular events (MACE)
Composite of angina pectoris, reinfarction, unplanned rehospitalization, stent thrombosis, incidence of cardiac death in the duration of follow-up
Time frame: maximum 5 years
Length of hospital stay
The length of in-hospital stay is counted as a secondary outcome
Time frame: in the phase of hospital stay, maximum 30 days
New-onset diabetes
New-onset diabetes are defined as newly-diagnosed type 2 diabetes mellitus
Time frame: the duration of follow-up, maximum 5 years
Plan to share: No — No plan to share data
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Provincial People's Hospital